ATLANTIC is the first study to study the efficacy of durvalumab in driver positive NSCLC, the results showed that patients with EGFR or ALK mutations had at least no lower OS than patients without EGFR or ALK mutations, at least when treated with durvalumab monotherapy.22 This evidence concerns the gene EGFR and non-small cell lung carcinoma.